Arrowhead says FDA grants plozasiran entry into STAR pilot program for severe hypertriglyceridemia sNDA

Bitget2026/10/07 11:31

FDA granted plozasiran entry into the STAR pilot program for an sNDA in severe hypertriglyceridemia. STAR acceptance positions the filing for a 6-month Priority Review, with a potential action at least one month earlier. Arrowhead targets year-end 2026 for the sNDA submission, keeping its Priority Review Voucher for another use or monetization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610070730BIZWIRE_USPR_____20261007_BW808152) on October 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%

Bitget•2026/11/09 08:14

Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high

Japan's spot electricity prices surged to multi-year highs over the weekend.

智通财经•2026/11/09 08:07

Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail

Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

智通财经•2026/11/09 07:32

Canaccord Genuity: Lowers Oklo's target price to $66

格隆汇•2026/11/09 07:01